Stocktoria
Q32 Bio Inc. QTTB
Q32 Bio Inc. (QTTB) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $53.7M at a 55.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.707 |
| Retained earnings / assets | -3.318 |
| EBIT / assets | 0.274 |
| Equity / liabilities | 2.126 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | 3/9 | -2.11 | 7.5 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | 2/9 | 12.52 | — | +48% |
| NKTR | NEKTAR THERAPEUTICS | 1/9 | — | — | -43.9% |
| XOMA | XOMA Royalty Corp | 5/9 | -11.82 | 23.3 | +83.1% |
| OCUL | OCULAR THERAPEUTIX, INC | 3/9 | 3.49 | — | -18.5% |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 3/9 | — | — | +60.2% |
| GOSS | Gossamer Bio, Inc. | — | — | — | -57.7% |
About Q32 Bio Inc.
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
FAQ
Is QTTB financially healthy?
Q32 Bio Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does QTTB pay a dividend?
No, Q32 Bio Inc. does not currently pay a dividend.
How profitable is QTTB?
In FY2025, Q32 Bio Inc. had a net margin of 55.5% and a return on equity of 71.0%.
What is QTTB's P/E ratio?
Q32 Bio Inc.'s trailing price-to-earnings (P/E) ratio is about 7.5×, based on its latest annual earnings.
What is the analyst price target for QTTB?
The average Wall-Street price target for Q32 Bio Inc. is $14.25, about 7.3% below the recent price, from 4 analysts.
Is QTTB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Q32 Bio Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone, a P/E of about 7.5×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.